Form 4: Evolent Health Director Brendan Springstubb Receives Significant Restricted Stock Unit Grant

Evolent Health, Inc. Director Brendan Springstubb was granted 21,979 restricted stock units on June 5, 2025, as part of the company's incentive compensation plan.

Summary

• Brendan B. Springstubb, a Director of Evolent Health, Inc. (EVH), acquired 21,979 shares of Class A Common Stock.
• This acquisition occurred on June 5, 2025, and represents a grant of restricted stock units (RSUs) with an acquisition price of $0 per share.
• Following this transaction, Mr. Springstubb directly beneficially owns a total of 48,821 shares.
• The granted RSUs are subject to vesting, which will occur on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent upon Mr. Springstubb's continued service.
• The grant was made pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a standard practice for aligning management and director interests with long-term shareholder value, indicating stability in compensation structure and a commitment to retention.

Positives

• The grant of restricted stock units to a director aligns their long-term interests with those of the shareholders, encouraging sustained performance and value creation.
• This transaction is part of a pre-existing, approved incentive compensation plan, indicating a structured approach to executive and director remuneration.

Risks

• The vesting of the restricted stock units is contingent on the reporting person's continued service, meaning the shares could be forfeited if service ceases before the vesting date.

Future Outlook

The granted restricted stock units are scheduled to vest on the earlier of June 5, 2026, or the date of the Company's 2026 annual meeting, contingent on the director's continued service.

Industry Context

The grant of restricted stock units is a common and widely accepted form of equity compensation for directors and executives across various industries, including healthcare technology, aiming to align their long-term financial interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• Grants of restricted stock units are a standard component of executive and director compensation packages in publicly traded companies, including those in the healthcare technology sector like Evolent Health.
• This practice is consistent with compensation strategies observed in peer companies such as Teladoc Health (TDOC) or Amwell (AMWL), which also utilize equity awards to incentivize long-term commitment and performance.
• The vesting schedule, tied to continued service and a future date, is typical for such awards, ensuring retention and alignment over a defined period.

Corporate Governance

Related Party Transactions

• This transaction represents an equity grant from Evolent Health, Inc. to Brendan B. Springstubb, a director of the company, which is a common form of related party compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of the 21,979 restricted stock units on the earlier of June 5, 2026, or the date of Evolent Health's 2026 annual meeting, subject to continued service.

Key Dates

Recommendation

Keywords

Evolent Health, EVH, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity grant, beneficial ownership